Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med, 357, 2666, 10.1056/NEJMoa072113

Miles, 2010, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J Clin Oncol, 28, 3239, 10.1200/JCO.2008.21.6457

Robert, 2011, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer, J Clin Oncol, 29, 1252, 10.1200/JCO.2010.28.0982

Brufsky, 2011, J Clin Oncol, 29, 4286, 10.1200/JCO.2010.34.1255

Crawford, 2009, VEGF inhibition: insights from preclinical and clinical studies, Cell Tissue Res, 335, 261, 10.1007/s00441-008-0675-8

Bagri, 2010, Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy, Clin Cancer Res, 16, 3887, 10.1158/1078-0432.CCR-09-3100

Grothey, 2008, Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE), J Clin Oncol, 26, 5326, 10.1200/JCO.2008.16.3212

Grothey, 2014, Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study, Pharmacoepidemiol Drug Saf, 23, 726, 10.1002/pds.3633

Cartwright, 2012, Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology, Clin Colorectal Cancer, 11, 238, 10.1016/j.clcc.2012.05.005

Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 14, 29, 10.1016/S1470-2045(12)70477-1

Masi, 2012, Ann Oncol, 23, ixe9, 10.1016/S0923-7534(20)34318-0

Fleming, 2009, Issues in using progression-free survival when evaluating oncology products, J Clin Oncol, 27, 2874, 10.1200/JCO.2008.20.4107

Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X

Baselga, 2012, Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer, J Clin Oncol, 30, 1484, 10.1200/JCO.2011.36.7771

von Minckwitz, 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study, J Clin Oncol, 27, 1999, 10.1200/JCO.2008.19.6618

Smith, 2011, Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial, Breast Cancer Res Treat, 130, 133, 10.1007/s10549-011-1695-8

Aogi, 2011, First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study, Breast Cancer Res Treat, 129, 829, 10.1007/s10549-011-1685-x

Ellis, 2009, Cancer: the nuances of therapy, Nature, 458, 290, 10.1038/458290a

Gridelli, 2011, Clin Lung Cancer, 12, 407, 10.1016/j.cllc.2011.05.002

Brandes, 2014, Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?, Future Oncol, 10, 1137, 10.2217/fon.14.75